- Home
- TRDA vs GHI Comparison
TRDA vs GHI Comparison
Compare TRDA & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- GHI
- Stock Information
- Founded
- TRDA 2016
- GHI 1998
- Country
- TRDA United States
- GHI United States
- Employees
- TRDA N/A
- GHI N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- GHI Finance: Consumer Services
- Sector
- TRDA Health Care
- GHI Finance
- Exchange
- TRDA Nasdaq
- GHI Nasdaq
- Market Cap
- TRDA 235.4M
- GHI 254.1M
- IPO Year
- TRDA 2021
- GHI N/A
- Fundamental
- Price
- TRDA $6.95
- GHI $8.27
- Analyst Decision
- TRDA Strong Buy
- GHI Strong Buy
- Analyst Count
- TRDA 3
- GHI 4
- Target Price
- TRDA $25.67
- GHI $14.88
- AVG Volume (30 Days)
- TRDA 187.5K
- GHI 123.5K
- Earning Date
- TRDA 11-06-2025
- GHI 11-06-2025
- Dividend Yield
- TRDA N/A
- GHI 17.90%
- EPS Growth
- TRDA N/A
- GHI N/A
- EPS
- TRDA N/A
- GHI N/A
- Revenue
- TRDA $79,476,000.00
- GHI $27,326,828.00
- Revenue This Year
- TRDA N/A
- GHI $223.15
- Revenue Next Year
- TRDA N/A
- GHI $5.11
- P/E Ratio
- TRDA N/A
- GHI N/A
- Revenue Growth
- TRDA N/A
- GHI N/A
- 52 Week Low
- TRDA $4.93
- GHI $8.20
- 52 Week High
- TRDA $21.79
- GHI $13.29
- Technical
- Relative Strength Index (RSI)
- TRDA 60.76
- GHI 14.56
- Support Level
- TRDA $6.60
- GHI $8.20
- Resistance Level
- TRDA $7.54
- GHI $8.72
- Average True Range (ATR)
- TRDA 0.43
- GHI 0.27
- MACD
- TRDA 0.06
- GHI -0.09
- Stochastic Oscillator
- TRDA 70.38
- GHI 3.66
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.